GeneDx Holdings Corp. $WGS Shares Acquired by Capital International Investors

Capital International Investors raised its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 182.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 283,248 shares of the company’s stock after purchasing an additional 182,964 shares during the quarter. Capital International Investors’ holdings in GeneDx were worth $36,839,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Arizona State Retirement System increased its stake in GeneDx by 2.1% during the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after purchasing an additional 113 shares in the last quarter. Main Management ETF Advisors LLC increased its stake in shares of GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after acquiring an additional 160 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after acquiring an additional 181 shares during the period. Jones Financial Companies Lllp increased its stake in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the period. Finally, Quarry LP increased its stake in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Up 8.7%

WGS stock opened at $56.33 on Wednesday. The firm has a market cap of $1.67 billion, a PE ratio of -21.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The firm’s fifty day moving average is $55.24 and its 200 day moving average is $91.57. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the prior year, the business posted ($0.23) EPS. On average, research analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on WGS. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Craig Hallum reiterated a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Guggenheim cut their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $96.43.

Insider Buying and Selling at GeneDx

In related news, Director Casdin Capital, Llc acquired 185,000 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the completion of the acquisition, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Keith A. Meister acquired 533,758 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were bought at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This represents a 16.53% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 2,256,420 shares of company stock worth $93,144,340 and have sold 72,382 shares worth $4,889,473. Company insiders own 29.60% of the company’s stock.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.